

SOHM Notes FDA's Evolving Gene-Editing Framework in Context of Ongoing ABBIE Platform Development.



CHINO HILLS, CALIFORNIA / ACCESS Newswire / November 4, 2025 / SOHM, Inc. (OTCID:SHMN), a pharmaceutical and biotechnology company specializing in generic drugs and gene-editing tools, a leader in Gene Editing and Cell Engineering is pleased to acknowledge recent FDA commentary and industry analyses signaling continued evolution of regulatory pathways for genome-editing technologies. These developments highlight increasing regulatory focus on precision-engineered genetic tools, non-viral delivery approaches, and scalable manufacturing frameworks.

SOHM is advancing its proprietary ABBIE™ genome-engineering platform, which is designed to enable DNA-insertion events through a programmable enzyme architecture. ABBIE is currently in preclinical development.

“As regulatory frameworks evolve, emphasis continues to be placed on genomic safety, process control, and manufacturing rigor,” said David Aguilar, COO of SOHM.

“ABBIE was designed to support controlled genomic engineering without the use of viral vectors, and our preclinical work continues to focus on establishing safety, mechanism, and reproducibility.”

For more information about SOHM Inc. and its groundbreaking work in biotechnology, please visit www.SOHM.com.

About SOHM, Inc.:

SOHM is a biopharmaceutical company dedicated to developing and commercializing gene editing technologies for research, synthetic biology, and therapeutic applications. With a focus on precision medicine, SOHM aims to revolutionize the treatment of genetic diseases by providing safe, efficient, and targeted gene editing solutions. Through strategic collaborations and groundbreaking research, SOHM is at the forefront of advancing the field of gene therapy. SOHM strives to transform the landscape of genome editing and improve the quality of life through scientific discovery.

For further information regarding this announcement or to explore potential collaborations, please contact:

SOHM, Inc.:

Name: Baron Night, CEO/Dr. David Aguilar, COO

Email: info@sohm.com

Phone: (714) 522-6700

Safe Harbor Statement:

This news release contains “forward-looking statements,” which are statements that are not purely historical and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development-stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report for the most recent fiscal year and our quarterly reports uploaded from time to time on OTCMarkets.com.